Antibody-drug conjugates (ADCs) continue to be one of the fastest-growing and most innovative areas in biopharmaceutical development.
Recent scientific publications highlight a clear evolution of the field, with increasing interest in next generation ADCs, including dual-payload constructs, bispecific ADCs, novel linker technologies, and applications extending beyond oncology.
While these advances offer significant therapeutic potential, they also introduce new analytical challenges. Unlike conventional biologics, ADCs combine the complexity of large molecules with highly potent small-molecule payloads. As a result, successful
quality control requires the integration of bioanalytical expertise with advanced small-molecule analytical capabilities: two disciplines that have traditionally been managed separately.
The emergence of increasingly sophisticated modalities, such as dual-payload ADCs, further amplifies this complexity. Multiple payloads, heterogeneous conjugation profiles and novel linker chemistries demand broader analytical knowledge and more comprehensive testing strategies throughout development.
Critical quality attributes (CQAs) such as drug-to-antibody ratio (DAR), linker stability, payload distribution, aggregation, free payload levels and biological activity must be carefully characterised and monitored from early development through commercial release. Regulatory agencies increasingly expect robust analytical packages capable of supporting development decisions, comparability assessments, stability programmes
and regulatory submissions.
At Eurofins BioPharma Product Testing, we support ADC programmes throughout the product lifecycle by combining expertise across biologics, small molecules, bioassays, stability studies, GMP testing and high-potency analytical services. Bringing these
complementary competencies together enables the development of integrated analytical strategies that provide a comprehensive understanding of product quality while supporting regulatory confidence.
As ADC technologies continue to evolve, analytical readiness becomes an increasingly important success factor. Building the right testing strategy early in development helps reduce risk, accelerate development timelines and generate meaningful, regulator-ready
data for increasingly complex ADC modalities.
The future of ADC development will undoubtedly bring new therapeutic opportunities.
Equally important will be the ability to generate meaningful, regulator-ready data that enables those innovations to reach patients safely and efficiently.
Contact us or visit our webpage to find out more about our ADC services.
Watch our video on cell-based assays.